Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Lung Cancer Screening and Prevention

Abstract PR04: Distinctive squamous cell carcinoma protein signatures.

Rachel Ostroff, Michael R. Mehan, Stephen Williams, Edward Brody, Harvey Pass, William Rom, Jill Siegfried, Thomas Muley, Wilbur Franklin, Dan Merrick, Adrie van Bokhoven, Holly Wolf, William Feser, Anna E. Barón and York Miller
Rachel Ostroff
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael R. Mehan
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Williams
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Brody
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harvey Pass
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Rom
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jill Siegfried
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Muley
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wilbur Franklin
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Merrick
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrie van Bokhoven
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly Wolf
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Feser
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna E. Barón
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
York Miller
1SomaLogic, Boulder, CO, 2NYU Langone Medical and Cancer Center, New York, NY, 3University of Minnesota, Minneapolis, MN, 4University Hospital Heidelberg, Heidelberg, Germany, 5University of Colorado Cancer Center, Denver, CO, 6University of Colorado Cancer Center and Denver Veterans Affairs Medical Center, Denver, CO.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.14AACRIASLC-PR04 Published January 2014
  • Article
  • Info & Metrics
Loading

Abstract

Squamous cell carcinoma (SQ) of the lung causes approximately 400,000 deaths per year worldwide, and no specifically targeted treatments yet exist. We used the SOMAscan proteomic platform (which measures 1129 proteins with a median limit of detection of 40 fM and 5% CV) in a broad-based analysis of serum and tissue samples to gain insight into the distinctive drivers of SQ malignant growth. We discovered unique SQ markers and pathways that show early expression of invasion and metastasis signals. Strong SQ signals were revealed. Our multi-center serum study of 94 non-small cell lung cancer (NSCLC) cases and 269 long-term smoker and benign pulmonary nodule controls resulted in the discovery of 60 lung cancer biomarkers and the development of a 7-marker diagnostic panel. This panel was validated in two independent cohorts. The AUC for detection of SQ carcinoma was 0.93 in training and 0.89 in the Univ. of Heidelberg validation set (56 SQ cases/27 benign nodule controls). Performance was confirmed with an AUC of 0.87 in an independent validation cohort assembled by the EDRN (25 SQ cases/20 benign nodules/52 smoker controls). This non-invasive test could be used as an adjunct to CT to detect rapidly growing SQ tumors that are disproportionately missed as interval cancers in CT screening studies. In addition, we analyzed 68 NSCLC tumor and matched non-tumor tissue lysates. This study consisted of 49 adenocarcinoma (AD) and 19 SQ tumors, 88% of which were Stage I or II. Proteomic comparisons of tumor/non-tumor or AD/SQ tissue samples performed using the Mann-Whitney test identified 79 tumor markers. Differences between tumor and non-tumor tissue were dominated by inflammatory, apoptotic and cell proliferation proteins. Just as we observed in the serum studies, the most common pattern was an increasing difference in protein levels from non tumor to AD to SQ. Of note, 24% of the proteins were only markers in SQ. These SQ-only markers are enriched for angiogenesis, cell proliferation and cell adhesion functions. Unexpected findings that the SQ proteome is dominated by proteins that promote malignancy and metastasis even in early stage tumors were revealed through broad proteomic profiling. These insights may lead to essential connections between the biochemical pathways altered in malignancy and tools for SQ cancer diagnosis and treatment.

This abstract is also presented as Poster B14.

Citation Format: Rachel Ostroff, Michael R. Mehan, Stephen Williams, Edward Brody, Harvey Pass, William Rom, Jill Siegfried, Thomas Muley, Wilbur Franklin, Dan Merrick, Adrie van Bokhoven, Holly Wolf, William Feser, Anna E. Barón, York Miller. Distinctive squamous cell carcinoma protein signatures. [abstract]. In: Proceedings of the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer; 2014 Jan 6-9; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2014;20(2Suppl):Abstract nr PR04.

  • ©2014 American Association for Cancer Research.
PreviousNext
Back to top
Clinical Cancer Research: 20 (2 Supplement)
January 2014
Volume 20, Issue 2 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract PR04: Distinctive squamous cell carcinoma protein signatures.
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract PR04: Distinctive squamous cell carcinoma protein signatures.
Rachel Ostroff, Michael R. Mehan, Stephen Williams, Edward Brody, Harvey Pass, William Rom, Jill Siegfried, Thomas Muley, Wilbur Franklin, Dan Merrick, Adrie van Bokhoven, Holly Wolf, William Feser, Anna E. Barón and York Miller
Clin Cancer Res January 15 2014 (20) (2 Supplement) PR04; DOI: 10.1158/1078-0432.14AACRIASLC-PR04

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract PR04: Distinctive squamous cell carcinoma protein signatures.
Rachel Ostroff, Michael R. Mehan, Stephen Williams, Edward Brody, Harvey Pass, William Rom, Jill Siegfried, Thomas Muley, Wilbur Franklin, Dan Merrick, Adrie van Bokhoven, Holly Wolf, William Feser, Anna E. Barón and York Miller
Clin Cancer Res January 15 2014 (20) (2 Supplement) PR04; DOI: 10.1158/1078-0432.14AACRIASLC-PR04
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Lung Cancer Screening and Prevention

  • Abstract A17: A blood test for early detection of lung cancer using a mixed panel of tumor proteins and autoantibodies.
  • Abstract PR08: Pro-surfactant protein B as a biomarker for lung cancer prediction.
  • Abstract IA10: Molecular testing to personalized EGFR and ALK inhibitor therapies in lung cancer.
Show more Lung Cancer Screening and Prevention

Oral Presentations - Proffered Abstracts

  • Abstract S07-03: Scientia potentia est: How the Italian world of oncology changes in the COVID19 pandemic
  • Abstract S05-01: Profound CD8 T-cell responses towards SARS-CoV-2 OFR1ab in COVID-19 patients
  • Abstract S10-01: COVID-19 severity and outcomes in hospitalized patients with cancer at a New York City tertiary medical center: A matched cohort study
Show more Oral Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement